The American Medical Association has approved two new Category III CPT codes for AI-assisted cardiac risk analysis.
We scan the top radiology sources so you don’t have to.
From AI breakthroughs to imaging trends, we serve up real-time radiology insights.
-
FDA Clears AI Assessment of Ischemic Core Volume on CT with Brainomix 360 Platform
For patients with acute ischemic stroke, research has demonstrated that automated assessment of ischemic core volume on brain CT scans via the Brainomix 360 software is equivalent to that derived from CT perfusion.
-
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
Emerging research from the recent Society of Interventional Radiology (SIR) conference suggests the combination of transarterial radioembolization (TARE) and immunotherapy may offer improved three-year survival outcomes for patients with breast cancer and liver metastases.
-
iCAD names new chief commercial officer
AI software developer iCAD has appointed Mark Koeniguer as its new chief commercial officer.
-
CT effective for tracking colon cancer lymph node distribution
Using CT to track lymph node distribution in colon cancer patients is more effective at identifying metastasis than conventional…
-
AI bests rads in finding breast cancer in women with personal history
AI may have a role in finding contralateral disease in women with a personal history of breast cancer.
-
Metabolic MRI technique shows promise in Alzheimer’s patients
Deuterium metabolic imaging was highly aligned with F-18 FDG-PET, a cornerstone of dementia diagnostics.
-
Role of imaging based response assesment for adapting neoadjuvant systemic therapy for breast cancer: A systematic review
Neoadjuvant systemic therapy (NST) has become the first-line treatment for locally advanced breast cancers and for selected cases of early-stage breast cancer. [1,2]. In addition to NST, the effectiveness of neoadjuvant endocrine therapy is being investigated in hormone receptor positive tumors. Furthermore, targeted therapies such as CDK4/6, PARP, and immune checkpoint inhibitors are under investigation [3,4].